English

• 8 Dec, 2025
  Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2026
• 24 Nov, 2025
  Spago Nanomedical announces outcome of oversubscribed rights issue
• 7 Nov, 2025
  The subscription period in Spago Nanomedical’s rights issue begins today
• 6 Nov, 2025
  Spago Nanomedical publishes information document in connection with forthcoming rights issue
• 29 Oct, 2025
  Spago Nanomedical resolves on a rights issue of approximately SEK 25 million to advance Tumorad
• 29 Oct, 2025
  Spago Nanomedical interim report January-September 2025
• 14 Oct, 2025
  Visible tumor uptake and recommended dose increase in Spago Nanomedicals’s Phase I/IIa study Tumorad-01
• 20 Aug, 2025
  Spago Nanomedical interim report January-June, 2025
• 3 Jun, 2025
  Spago Nanomedical continues patient recruitment in the phase I/IIa study Tumorad-01 as planned after DMC recommendation
• 14 May, 2025
  Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB